



## Ardelyx to Present at the Jefferies 2022 Healthcare Conference

June 3, 2022

WALTHAM, Mass., June 3, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022, at 8:30 a.m. ET in New York City.



To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at [ir.ardelyx.com](http://ir.ardelyx.com). A replay of the webcast will be available on the Ardelyx website for 30 days following the conference.

### About Ardelyx, Inc.

Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA<sup>®</sup> (tenapanor) is available in the United States. Ardelyx is developing XPHOZAH<sup>®</sup> (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium secretagogue program, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-jefferies-2022-healthcare-conference-301560772.html>

SOURCE Ardelyx

Investor and Media Contacts: Kimia Keshtbod, [kkeshtbod@ardelyx.com](mailto:kkeshtbod@ardelyx.com); Sylvia Wheeler, Wheelhouse Life Science Advisors, [swheeler@wheelhousesa.com](mailto:swheeler@wheelhousesa.com); Alex Santos, Wheelhouse Life Science Advisors, [asantos@wheelhousesa.com](mailto:asantos@wheelhousesa.com)